High Expression of Macrophage Colony-Stimulating Factor-1 Receptor in Peritumoral Liver Tissue is Associated with Poor Outcome in Hepatocellular Carcinoma after Curative Resection

Jin-Bin Jia,Wen-Quan Wang,Hui-Chuan Sun,Xiao-Dong Zhu,Liang Liu,Peng-Yuan Zhuang,Ju-Bo Zhang,Wei Zhang,Hua-Xiang Xu,Ling-Qun Kong,Lu,Wei-Zhong Wu,Lu Wang,Zhao-You Tang
DOI: https://doi.org/10.1634/theoncologist.2009-0170
2010-01-01
Abstract:Background. Macrophage colony-stimulating factor 1 receptor (CSF-1R) expression in hepatocellular carcinoma (HCC) and its prognostic values are unclear. This study evaluated the prognostic values of the intratumoral and peritumoral expression of CSF-1R in HCC patients after curative resection.Methods. Tissue microarrays containing material from cohort 1 (105 patients) and cohort 2 (32 patients) were constructed. Immunohistochemistry was performed and prognostic values of these and other clinicopathological data were evaluated. The CSF-1R mRNA level was assessed by quantitative real-time polymerase chain reaction in cohort 3 (52 patients).Results. Both the CSF-1R density and its mRNA level were significantly higher in peritumoral liver tissue than in the corresponding tumor tissue. CSF-1R was distributed in a gradient in the long-distance peritumoral tissue microarray, with its density decreasing as the distance from the tumor margin increased. High peritumoral CSF-1R was significantly associated with more intrahepatic metastases and poorer survival. Peritumoral CSF-1R was an independent prognostic factor for both overall survival and time to recurrence and affected the incidence of early recurrence. However, intratumoral CSF-1R did not correlate with any clinicopathological feature. Peritumoral CSF-1R was also associated with both overall survival and time to recurrence in a subgroup with small HCCs (<= 5 cm).Conclusions. Peritumoral CSF-1R is associated with intrahepatic metastasis, tumor recurrence, and patient survival after hepatectomy, highlighting the critical role of the peritumoral liver milieu in HCC progression. CSF-1R may become a potential therapeutic target for postoperative adjuvant treatment. The Oncologist 2010;15:732-743
What problem does this paper attempt to address?